Health TrialsbyHealthPanel

Dexamethasone Versus Metoclopramide for Prophylaxis of Nausea and Vomiting After Cataract Surgery

ConditionsCataractDexamethasone
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-80
SponsorAlexandria University

About this trial

Postoperative nausea and vomiting (PONV) is a common consequence of ambulatory surgery, affecting up to 80% of high-risk patients and 20-30% overall. Despite being widespread, a prior survey found that patients are more averse to PONV than pain and other significant postoperative problems. Furthermore, even mild cases of PONV can have serious repercussions, such as postanesthesia care unit (PACU) workflow disruption, delayed discharges, higher medical costs, and lower patient satisfaction.PONV following intraocular surgery can be unpleasant and may lead to serious complications including suprachoroidal hemorrhage (SCH). SCH is a potentially serious condition that occurs when the posterior ciliary arteries or vortex veins burst, resulting in blood in the suprachoroidal region.

The hypothesis is that dexamethasone will lower the incidence of PONV after cataract surgery when compared with metoclopramide.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age: 40-80 years, both sexes.

ASA physical status class I to III.

Disqualifiers

history of motion sickness

patients with gastrointestinal disorders or gastro-oesophageal reflux

patients taking medications with known antiemetic activity

previous postoperative vomiting

Trial design

Design model

Parallel

Treatments tested in this trial

  • 0.9% normal saline

    Other intervention

    patients in group P will receive 0.9% normal saline

  • Metoclopramide 10mg

    Drug

    patients in group M will receive 10 mg metoclopramide

  • Dexamethasone

    Drug

    patients in group D will receive 8 mg dexamethasone

Treatment groups

210 Participants
are divided into 3 treatment groups
Group A: group pPlacebo comparator 1 intervention
Group B: group MActive comparator 1 intervention
Group C: group DActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

number of patients with nausea and vomiting

number

Time frame
postoperative day 1

Secondary outcomes

1

vas score

score

Time frame
postoperative day 1
2

number of patients requiring antiemetic

number

Time frame
postoperative day1
3

incidence of dizziess, pruritis and headache

number

Time frame
postoperative day 1

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Alexandria University

Lead sponsor

Source ClinicalTrials.gov
Apply now